Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata (AA)
Efficacy of Tacrolimus and Clobetasol Propionate in the Treatment of Alopecia Areata
DOI:
https://doi.org/10.54393/pjhs.v4i11.1168Keywords:
Alopecia Areata, Clobetasol Propionate, TacrolimusAbstract
Alopecia areata patients can choose from a variety of therapy methods. Each method has advantages and limitations, and its suitability varies for each patient. The medical usefulness of topical corticosteroids in AA is yet debatable. Objective: To assess the effectiveness of topical tacrolimus 0.1% vs. topical clobetasol propionate 0.05% while treating alopecia areata. Methods: Randomized-controlled trial (Double blind) conducted in Dermatology Department, CMH-Abbottabad, from November 2022 to April 2023. The seventy (70) patients with alopecia areata who attended to OPD of CMH Abbottabad between the ages of 20 and 50 were included. The non-probability consecutive sampling method was used. For up to 3 months, patients in Group A used clobetasol propionate 0.05% twice daily, while patients in Group B used topical tacrolimus 0.1% twice daily. Patients were evaluated at the start of each session, four weeks later, eight weeks later, and twelve weeks later. The SALT score was used to estimate hair loss at presentation and during the 3-month follow-up. The degree of response has been characterized by following hair re-growth as excellent (>75%), marked (51-75%), moderate (26-50%), or mild (25%). A p-value of <0.05 was considered significant. Results: When the efficacy was compared, 26 (74.3%) patients in group-A (mean age 35.23+7.87 years) shown excellent response, while 14 (40%) patients in group-B (mean age 34.29+7.87 years) with significant p-value was 0.028. Conclusions: Clobetasol propionate 0.05% was more efficacious as a therapy choice for stimulating hair re-growth in patients.
References
Gharib K and Elsayed A. Serum level of interleukin-17A in patients with alopecia areata and its relationship to age of patients and disease recurrence. Egyptian Journal of Dermatology and Venerology. 2021 Jul; 41(2): 83. doi: 10.4103/ejdv.ejdv_24_20. DOI: https://doi.org/10.4103/ejdv.ejdv_24_20
Rehman S and Jameel R. Appearance anxiety and loneliness: the mediating role of rejection sensitivity in patients with alopecia areata in Lahore Pakistan. JPMA. The Journal of the Pakistan Medical Association. 2023 Apr; 73(4): 800-3. doi: 10.47391/JPMA.6302. DOI: https://doi.org/10.47391/JPMA.6302
Malakar S, Banerjee U, Mehta P, Mukherjee S, Sardar S, Malakar S, et al. Trichoscopy. Atlas of Dermatology, Dermatopathology and Venereology: Cutaneous Anatomy, Biology and Inherited Disorders and General Dermatologic Concepts. 2021 Oct: 295-322. doi: 10.1007/978-3-319-53811-2_93. DOI: https://doi.org/10.1007/978-3-319-53811-2_93
Al-Hamamy HR and Al-Ani GN. Nail Changes in Alopecia Areata and Their Correlation with Disease Severity. Iraqi Postgraduate Medical Journal. 2021; 20(2): 128-35.
Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clinical Reviews in Allergy & Immunology. 2021 Dec; 61(3): 403-423. doi: 10.1007/s12016-021-08883-0. DOI: https://doi.org/10.1007/s12016-021-08883-0
Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines–Part II. Journal of the American Academy of Dermatology. 2004 Sep; 51(3): 440-7. doi: 10.1016/j.jaad.2003.09.032. DOI: https://doi.org/10.1016/j.jaad.2003.09.032
Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. Journal of Autoimmunity. 2019 Mar; 98: 74-85. doi: 10.1016/j.jaut.2018.12.001. DOI: https://doi.org/10.1016/j.jaut.2018.12.001
Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. The Journal of Dermatology. 2022 Jan; 49(1): 19-36. doi: 10.1111/1346-8138.16207. DOI: https://doi.org/10.1111/1346-8138.16207
Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. Journal of the American Academy of Dermatology. 2020 Jul; 83(1): 123-30. doi: 10.1016/j.jaad.2020.03.004. DOI: https://doi.org/10.1016/j.jaad.2020.03.004
Umar BU, Rahman S, Dutta S, Islam T, Nusrat N, Chowdhury K, et al. Management of Atopic Dermatitis: The Role of Tacrolimus. Cureus. 2022 Aug; 14(8): e28130. doi: 10.7759/cureus.28130. DOI: https://doi.org/10.7759/cureus.28130
Ullah F, Dawood M, Noor N, Hameed S. Efficacy of Topical Clobetasol Propionate 0.05% Ointment and Topical Tacrolimus 0.1% Ointment in Treatment of Alopecia Areata.: RCT. Pakistan Journal of Medical & Health Sciences. 2022 Jun; 16(06): 133. doi: 10.53350/pjmhs22166133. DOI: https://doi.org/10.53350/pjmhs22166133
Sotiriou E, Patsatsi A, Fotiadou C, Sotiriadis D, Panagiotidou D. Tacrolimus ointment 0.1% in the treatment of active patchy alopecia areata of childhood. European Journal of Pediatric Dermatology. 2007 Dec; 17(4): 227-30.
Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. Journal of the American Academy of Dermatology. 1998 Nov; 39(5): 751-61. doi: 10.1016/S0190-9622(98)70048-9. DOI: https://doi.org/10.1016/S0190-9622(98)70048-9
Hossain MS, Miah MT, Khan MZ, Khondker L, Hasan MR. Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata. Journal of Pakistan Association of Dermatologists. 2015; 25(3): 197-201.
Shakhawat H, Titu M, Zulfiqur Hossain K, Lubna K, Rashidul H. Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata. Journal of Pakistan Association of Dermatologists. 2016 Nov; 25(3): 197-201.
Alshahrani AA, Al-Tuwaijri R, Abuoliat ZA, Alyabsi M, AlJasser MI, Alkhodair R. Prevalence and clinical characteristics of alopecia areata at a tertiary care center in Saudi Arabia. Dermatology Research and Practice. 2020 Mar; 2020: 7194270. doi: 10.1155/2020/7194270. DOI: https://doi.org/10.1155/2020/7194270
You HR and Kim SJ. Factors associated with severity of alopecia areata. Annals of Dermatology. 2017 Oct; 29(5): 565-70. doi: 10.5021/ad.2017.29.5.565. DOI: https://doi.org/10.5021/ad.2017.29.5.565
Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2019 Feb; 80(2): 466-77. doi: 10.1016/j.jaad.2018.07.013. DOI: https://doi.org/10.1016/j.jaad.2018.07.013
Mian M, Silfvast-Kaiser A, Paek S, Kivelevitch D, Menter A. A review of the most common dermatologic conditions and their debilitating psychosocial impacts. International Archives of Internal Medicine. 2019 Jul; 3: 18. doi: 10.23937/2643-4466/1710018. DOI: https://doi.org/10.23937/2643-4466/1710018
Chanprapaph K, Mahasaksiri T, Kositkuljorn C, Leerunyakul K, Suchonwanit P. Prevalence and risk factors associated with the occurrence of autoimmune diseases in patients with alopecia areata. Journal of Inflammation Research. 2021 Sep; 14: 4881. doi: 10.2147/JIR.S331579. DOI: https://doi.org/10.2147/JIR.S331579
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
